Ahmed, Khalil <br/><br/>
CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.  [electronic resource] 

 -  Oncotarget  Sep 2016 
 - 61789-61805 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.11442  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Cell Death<br/>Cell Line, Tumor<br/>Cell Proliferation<br/>Drug Delivery Systems<br/>Humans<br/>Male<br/>Mice<br/>Mice, Inbred NOD<br/>Mice, Nude<br/>Mice, SCID<br/>Nanocapsules--chemistry<br/>Peptide Fragments--chemistry<br/>Prostatic Neoplasms--drug therapy<br/>RNA Interference<br/>RNAi Therapeutics<br/>Signal Transduction<br/>Tenascin--chemistry<br/>Xenograft Model Antitumor Assays